PARKINSON'S DISEASE NEUROPROTECTION CLINICAL TRIAL

帕金森病神经保护临床试验

基本信息

批准号：
7558065
负责人：
KAPIL D SETHI
金额：
$ 6.55万
依托单位：
AUGUSTA UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2002
资助国家：
美国
起止时间：
2002-09-30 至 2012-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7558065
关键词：
2beta-carbomethoxy-3beta-(4-iodophenyl)tropane Address Age Antipsychotic Agents Appearance Area Attention Autopsy Caring Cells Cessation of life Chlorpromazine Clinic Clinical Clinical Trials Communities Condition Diagnosis Disease Dopaminergic Agents Dopaminergic Cell Dose Drug Prescriptions Education Elderly Evaluation Evolution Exposure to Family Family history of Frequencies Functional disorder General Population Genetic Geriatrics Historical Cohort Studies Individual Lewy Bodies Lewy Body Disease Medical Medical center Movement Disorders Nature Neurologist Neurology Newly Diagnosed Numbers Onset of illness Outcome Parkinson Disease Parkinsonian Disorders Patients Pharmaceutical Preparations Population Positron-Emission Tomography Predisposition Primary Health Care Provider Psychotic Disorders Qualifying Quality of life Range Recovery Relative Risks Reporting Research Retrospective Studies Scanning Series Services Staging Support Groups Symptoms System Thinking USA Georgia Veterans Western Asia Georgia Withdrawal base cohort college day dosage drug development experience follow-up hydroxy-aluminum polymer neuroprotection pre-clinical prevent programs single photon emission computed tomography uptake

项目摘要

DESCRIPTION (provided by applicant): Specific Aim: To participate in the clinical trial of neuroprotection in Parkinson's disease (PD) as a clinical center. Summary:The Medical College of Georgia (MCG) Movement Disorders Clinic (MDC) is uniquely qualified to be a clinical center for the proposed neuroprotective trial in Parkinson's Disease (PD) because of the varied patient population. The clinic has been operational since 1985 at the MCG and the Augusta Veterans Affairs Medical Center (VAMC). Over 700 patients with PD who are in both early and advanced stages of the disease are evaluated and treated each year at MCG and the VAMC. Kapil D. Sethi, MD, FRCP (UK) and the entire research team have extensive experience in caring for PD patients and conducting clinical drug and research trials. The existing referral base is strong, consisting of general neurologists in the local area and surrounding Primary Care Providers. The local PD support group was started ten years ago under the guidance of the Dr. Sethi. The support group is actively involved with the MDC and is helpful in the education of newly diagnosed PD patients and their families. Long-Term Objectives:1. To delay the progression of PD through the use of medications while maintaining quality of life.2. Discover indicators of those susceptible to PD and prevent or delay onset of the disease.3. Ultimately, find a cure for PD.

描述（由申请人提供）：具体目的：参与帕金森氏病（PD）作为临床中心的神经保护的临床试验。摘要：佐治亚州医学院（MCG）运动障碍诊所（MDC）由于患者人群的多样化而被典型地成为帕金森氏病（PD）的拟议神经保护试验的临床中心。该诊所自1985年以来一直在MCG和奥古斯塔退伍军人事务医疗中心（VAMC）运营。每年在MCG和VAMC中评估和治疗700多名处于早期和晚期阶段的PD患者。医学博士Kapil D. Sethi（英国）和整个研究团队在照顾PD患者并进行临床药物和研究试验方面拥有丰富的经验。现有的推荐基础很强，由当地和周围初级保健提供者的一般神经科医生组成。当地的PD支持小组于十年前在Sethi博士的指导下成立。支持小组积极参与MDC，并有助于对新诊断的PD患者及其家人的教育。长期目标：1。通过使用药物来延迟PD的进展，同时保持生活质量。2。发现容易患PD的人的指标，并预防或延迟疾病发作3。最终，找到治疗PD的方法。